0001104659-16-159822.txt : 20161130
0001104659-16-159822.hdr.sgml : 20161130
20161130194804
ACCESSION NUMBER: 0001104659-16-159822
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20161129
FILED AS OF DATE: 20161130
DATE AS OF CHANGE: 20161130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aegerion Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001338042
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 202960116
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE MAIN STREET
STREET 2: SUITE 800
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (617) 500-7867
MAIL ADDRESS:
STREET 1: ONE MAIN STREET
STREET 2: SUITE 800
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Aegerion Pharmaceuticals Inc
DATE OF NAME CHANGE: 20050906
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Scheer David
CENTRAL INDEX KEY: 0001378585
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34921
FILM NUMBER: 162026504
MAIL ADDRESS:
STREET 1: ACHILLION PHARMACEUTICALS
STREET 2: 300 GEORGE STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06511
4
1
a4.xml
4
X0306
4
2016-11-29
1
0001338042
Aegerion Pharmaceuticals, Inc.
AEGR
0001378585
Scheer David
C/O AEGERION PHARMACEUTICALS, INC.
ONE MAIN STREET, SUITE 800
CAMBRIDGE
MA
02142
1
0
0
0
Common Stock
2016-11-29
4
D
0
10000
D
0
D
Common Stock
2016-11-29
4
D
0
521350
D
0
I
See Footnote
Stock Option (Right to Buy)
17.64
2016-11-29
4
D
0
9988
D
2014-06-01
2021-06-01
Common Stock
9988
0
D
Stock Option (Right to Buy)
15.00
2016-11-29
4
D
0
12854
D
2015-06-05
2022-06-05
Common Stock
12854
0
D
Stock Option (Right to Buy)
64.73
2016-11-29
4
D
0
14700
D
2014-06-26
2023-06-26
Common Stock
14700
0
D
Stock Option (Right to Buy)
32.55
2016-11-29
4
D
0
5012
D
2015-06-26
2024-06-26
Common Stock
5012
0
D
Stock Option (Right to Buy)
17.98
2016-11-29
4
D
0
18000
D
2016-06-26
2025-06-26
Common Stock
18000
0
D
Disposed of in exchange for 10,256 common shares of Novelion Therapeutics Inc. ("Novelion") pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective November 29, 2016. Following completion of the merger, QLT was renamed "Novelion Therapeutics Inc."
Disposed of in exchange for 534,696 common shares of Novelion pursuant to the Merger Agreement.
Shares were held by Scheer Investment Holdings VII, LLC. The Reporting Person is the managing member of Scheer Investment Holdings VII, LLC. Mr. Scheer disclaimed beneficial ownership of such shares except to the extent of his proportionate pecuniary interest therein.
Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor.
/s/ Jennifer Fitzpatrick, Attorney-in-fact
2016-11-30